News zum Sektor Gesundheit aus Norwegen

 

Oslo, August 22, 2025 - Observe Medical ("the Company" or "Observe Medical") today releases its results for the first half of 2025. The Company will host a presentation with a trading update Tuesday, 23 September 2025. Financial highlights · Operating revenues amounted to NOK 11.3 million, supported by a 61% increase in sales of the UnoMeter™ product family YoY driven by the introduction of UnoMeter™ Safeti™ Plus, offset by the discontinuation of the Nordic distribution business · Operating result before depreciation and amortisation (EBITDA) of negative NOK 8.7 million, an...

Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA....

Oncoinvent will present operational and financial update for the first half of 2025 on Wednesday 27 August 2025 at 08:00am (CET). The presentation will be live streamed in English followed by a Q&A session. The presentation is available on https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/ (https://eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fchannel.royalcast.com%2Flandingpage%2Fhegnarmedia%2F20250827_3%2F&data=05%7C02%7Ckvam%40oncoinvent.com%7C5f4c92e2cb894c93f5e608ddbd38a461%7C6da5bf1fbdf44dbb949301c5dcdde30e%7C0%7C0%7C638874773164979877%7CUnknown%...

HBC recorded total operating revenues of NOK 68.4 million in the second quarter of 2025, compared to NOK 80.4 million in the same period last year. Net operating revenues were NOK 67.8 million, compared to NOK 72.2 million in the same quarter last year. Total operating revenue for the first six months of 2025 was NOK 129.3 million (NOK 132.8 million)....

Oslo, August 21, 2025 – Observe Medical ("the Company" or "Observe Medical") has received additional orders from the distributor in Switzerland after several successful hospital conversions and also receives first orders from new distributor in Slovenia after hospital product evaluations. Jørgen Mann, CEO of Observe Medical, commented: " The Swiss market is a very critical market in terms of product performance and quality which is why we are very happy that UnoMeter™ Safeti™ Plus has now again been confirmed as superior when compared to our competitors and as a great fit with customer...

Lytix Biopharma AS (Euronext Growth Oslo: LYTIX), a leading Norwegian immuno-oncology company, will release its second quarter 2025 financial results on Thursday, August 28th, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the results and provide key insights.   Date: Thursday, August 28th, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A session following the presentation....

Arctic Bioscience will publish its financial results for the first half year of 2025 on Thursday 28[th] of August, at 08:00 CET. The same day at 11:00 CET, the Company will host a webcast to present the results and give an operational update. Following the presentation, it will be opened for questions from the audience. Webcast details: Date: Thursday 28[th] of August 2025 Time: 11:00 CET Format: Webcast and Q&A Language: Norwegian/English The presentation can be accessed through the Company's website, or with the link below: Link:  https://teams.microsoft.com/l/meetup-...

Helsinki, Finland, 20 August 2025: Karan Wallia, a primary insider of Nordhealth AS (the "Company"), has purchased class A shares in the Company. Please refer to the attached notification of trading for further details. For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander Cram, CFO alexander.cram@nordhealth.com +32 470 69 30 20 This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014 Article 19 and the Norwegian Securities Trading Act Section 5-12....

Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today....

Bergen, Norway, 20 August 2025 – BerGenBio ASA (OSE: BGBIO today announced financial results for the first half 2025.   Highlights, including post period:   · In February, following a preliminary analysis of response data, BerGenBio decided to close its lead clinical study, BGBC016, in bemcentinib in combination with standard of care therapy in first line (1L) non-squamous Non-Small Cell Lung Cancer (NSCLC) patients with a mutation in the STK11 gene. · The company has implemented significant cost-containment and cash-conservation measures. The Board of Directors has also...

Please find attached the presentation of Nordhealth AS Q2/2025 results, and the interim financial report of Nordhealth AS for H1/2025. The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19th of August 2025 at 16:30 CEST. Please use the following link to attend: https://us02web.zoom.us/j/86765127004 The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Alexander...

Oslo (Norway), 18 August 2025 – PCI Biotech Holding ASA (PCI Biotech, OSE:PCIB) today announces the discontinuation of development of the photochemical lysis (PCL) technology for viral vector manufacturing. ...

Arctic Bioscience today announced that a clinical study published in International Ophthalmology demonstrated that daily supplementation with ROMEGA® herring caviar oil resulted in a statistically significant improvement in the visual field measure Mean Deviation (MD) in patients with primary open-angle glaucoma (POAG) and controlled intraocular pressure (IOP). No adverse events were observed, and the treatment was well tolerated. About the study The three-month study included 50 patients. The intervention group received one ROMEGA® capsule (500mg) daily. Results showed a clear...

Oslo, Norway, 15th of August 2025...

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic 'off the shelf' T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation of its second quarter 2025 results, on Wednesday, August 20, 2025....

OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down......

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company's commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and...

Helsinki, Finland - August 13, 2025 - Nordhealth is increasing its investments in product development for AI and DACH localisation in 2025: 1. Accelerating the localisation of flagship veterinary practice management software, Provet Cloud, into DACH markets: The company believes that the market for veterinary enterprise clients in DACH is increasingly compelling. Additionally, the company believes that the evolving differences in service quality and profitability, between Provet Cloud, and Nordhealth's acquired DACH legacy platform, Vetera, justify accelerating the groundwork to migrate...

Nordhealth will report and present its Q2 2025 results on Tuesday the 19[th] of August 2025. The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19[th] of August at 16:30 CEST. Please use the following link to attend: https://us02web.zoom.us/j/86765127004 The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q2/2025 will be available on 19[th] August 2025 at 08:30 CEST on www.newsweb.no (https://publish.ne.cision.com/l/afkpudtpe/www.newsweb.no) and...

OSLO, Norway, Aug. 13, 2025 /PRNewswire/ -- Navamedic is pleased to announce that it has received final approval for the packaging material in national languages for Norway, Sweden and Denmark, following the earlier announcement on June 27th. Orion Corporation ("Orion"), the product......